PURPOSE. We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count. METHODS. Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs). RESULTS. We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively). CONCLUSIONS. We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease. © 2006 Wiley-Liss, Inc.

Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients / Sciarra, Alessandro; Lichtner, Miriam; Autran Gomez, A.; Mastroianni, Claudio Maria; Rossi, Raffaella; Fabio, Mengoni; Cristini, Cristiano; Gentilucci, Alessandro; Vullo, Vincenzo; DI SILVERIO, Franco. - In: THE PROSTATE. - ISSN 0270-4137. - 67:1(2007), pp. 1-7. [10.1002/pros.20431]

Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients

SCIARRA, Alessandro
;
LICHTNER, Miriam;MASTROIANNI, Claudio Maria;ROSSI, RAFFAELLA;CRISTINI, Cristiano;Alessandro Gentilucci;VULLO, Vincenzo;DI SILVERIO, Franco
2007

Abstract

PURPOSE. We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count. METHODS. Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs). RESULTS. We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively). CONCLUSIONS. We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease. © 2006 Wiley-Liss, Inc.
dendritic cells; gleason score; immunotherapy; prostate cancer; psa
01 Pubblicazione su rivista::01a Articolo in rivista
Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients / Sciarra, Alessandro; Lichtner, Miriam; Autran Gomez, A.; Mastroianni, Claudio Maria; Rossi, Raffaella; Fabio, Mengoni; Cristini, Cristiano; Gentilucci, Alessandro; Vullo, Vincenzo; DI SILVERIO, Franco. - In: THE PROSTATE. - ISSN 0270-4137. - 67:1(2007), pp. 1-7. [10.1002/pros.20431]
File allegati a questo prodotto
File Dimensione Formato  
Sciarra_Characterization_2007.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 219.29 kB
Formato Adobe PDF
219.29 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/363698
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 32
social impact